211 related articles for article (PubMed ID: 30975912)
21. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
[TBL] [Abstract][Full Text] [Related]
22. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
23. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
24. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
Ling Q; Li F; Zhang X; Mao S; Lin X; Pan J; Ye W; Wei W; Qian Y; Hu C; Huang X; Wang J; Wang H; Huang J; Wang Y; Jin J
EBioMedicine; 2021 Jul; 69():103441. PubMed ID: 34166980
[TBL] [Abstract][Full Text] [Related]
25. RSK Inhibition Induces Apoptosis by Downregulating Protein Synthesis in a Variety of Acute Myeloid Leukemia Cell Lines.
Katayama K; Nishihata A
Biol Pharm Bull; 2021 Dec; 44(12):1843-1850. PubMed ID: 34602526
[TBL] [Abstract][Full Text] [Related]
26. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.
Liu S; Yin L; Stroopinsky D; Rajabi H; Puissant A; Stegmaier K; Avigan D; Kharbanda S; Kufe D; Stone R
Blood; 2014 Jan; 123(5):734-42. PubMed ID: 24282218
[TBL] [Abstract][Full Text] [Related]
27. Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine.
Shao J; Shah S; Ganguly S; Zu Y; He C; Li Z
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372359
[TBL] [Abstract][Full Text] [Related]
28. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
29. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
30. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
31. Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo.
Cao ZX; Wen Y; He JL; Huang SZ; Gao F; Guo CJ; Liu QQ; Zheng SW; Gong DY; Li YZ; Zhang RQ; Chen JP; Peng C
Mol Pharmacol; 2019 Nov; 96(5):589-599. PubMed ID: 31462456
[TBL] [Abstract][Full Text] [Related]
32. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.
Sun YM; Wang WT; Zeng ZC; Chen TQ; Han C; Pan Q; Huang W; Fang K; Sun LY; Zhou YF; Luo XQ; Luo C; Du X; Chen YQ
Blood; 2019 Oct; 134(18):1533-1546. PubMed ID: 31387917
[TBL] [Abstract][Full Text] [Related]
33. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
34. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression.
Zhang D; Guo Y; Zhao Y; Yu L; Chang Z; Pei H; Huang J; Chen C; Xue H; Xu X; Pan Y; Li N; Zhu C; Zhao ZJ; Yu J; Chen Y
Microb Cell Fact; 2021 Mar; 20(1):67. PubMed ID: 33691697
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
36. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
[TBL] [Abstract][Full Text] [Related]
37. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
38. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.
Qu S; Liu B; Guo X; Shi H; Zhou M; Li L; Yang S; Tong X; Wang H
Cancer; 2014 Jul; 120(14):2130-41. PubMed ID: 24737397
[TBL] [Abstract][Full Text] [Related]
39. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
40. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
Zhang X; Li B; Yu J; Dahlström J; Tran AN; Björkholm M; Xu D
Ann Hematol; 2018 Jan; 97(1):63-72. PubMed ID: 29080039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]